MedPath

Indian Trial of Tranexamic acid in Spontaneous intracerebral haemorrhage

Phase 4
Conditions
Health Condition 1: I610- Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
Registration Number
CTRI/2023/03/050224
Lead Sponsor
Indian Council of Medical Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Adult patients aged more than 18 years of age presenting with non-traumatic intracerebral haemorrhage within 4.5 hours of symptom onset.

Exclusion Criteria

1.Patients with intracerebral haemorrhage secondary to anticoagulation, thrombolysis or known underlying structural abnormality such as arteriovenous malformation, aneurysm, tumour or venous thrombosis or due to known hereditary coagulation disorders. An underlying structural abnormality does not need to be excluded before enrolment, but where known, patients should not be recruited.

2.Known allergies to Tranexamic acid.

3.Modified Rankin scale score >4 at the time of enrollment

4.Concurrent participation in another drug or device trial.

5.Pre stroke life expectancy <3 months (e.g. advanced metastatic cancer).

6.Glasgow coma scale <7.

7.ICH secondary to trauma.

8.Women pregnant,or breastfeeding at randomization.

9.Geographical or other factors that prohibit follow up at 90 days, e.g. no fixed address or telephone contact number, or overseas visitor.

10.Planned surgery for ICH within 24 hours.

11.Concurrent or planned treatment with any other haemostatic agents.

12.ICH volume >60 ml as measured by the ABC/2 method.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Death at day 7Timepoint: 7 Days
Secondary Outcome Measures
NameTimeMethod
1)Radiological (CT scan): Change in hematoma volume from baseline to 24 h scan, hematoma location, and new infarction.Timepoint: 24 hours;2)Neurological impairment (NIHSS) at day 7 (or discharge if sooner).Timepoint: Day 7;3)Dependency using the seven-level modified Rankin Scale (mRS) at day 90Timepoint: 90 Days;4)Quality of Life ( EQ-5D) at days 90Timepoint: 90 Days
© Copyright 2025. All Rights Reserved by MedPath